ArticleScience advances2026
High-fidelity genotyping and therapeutic oligonucleotides analysis by liquid-phase ion trap coupled with mass spectrometry.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid and accurate nucleic acid analysis is essential for disease diagnostics and drug development, yet persistent metal cation interference severely limits mass spectrometry's effectiveness. We developed a liquid-phase ion trap (LPIT) system that utilizes strong electric fields to simultaneously dissociate metal contaminants and enrich purified nucleic acid ions directly in solution. This dual-action mechanism simplifies complex mass spectra, achieving up to a 48-fold improvement in mass accuracy and a 100-fold enhancement in signal intensity for intact DNA molecules. The platform's versatility was demonstrated through high-resolution genetic variation analysis, rapid influenza virus subtyping from raw PCR products, and precise impurity detection in therapeutic drugs. By eliminating laborious pretreatment, the LPIT-ESI-MS system establishes a robust platform for high-fidelity genotyping and the rigorous analysis of therapeutic oligonucleotides, accelerating both clinical diagnostics and biopharmaceutical quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.